ITSA-1|cas:200626-61-5|西域试剂

ITSA-1,98.0%

产品编号：Bellancom-100508| CAS NO：200626-61-5| 分子式：C₁₃H₇Cl₂N₃O| 分子量：292.12

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-100508	￥500.00	杭州北京（现货）
Bellancom-100508	￥850.00	杭州北京（现货）
Bellancom-100508	￥1300.00	杭州北京（现货）
Bellancom-100508	￥2200.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

ITSA-1

产品介绍

ITSA-1 是 HDAC 的激活剂，可抵消曲古抑菌素 A (trichostatin A, TSA) 诱导的细胞周期停滞，组蛋白乙酰化和转录水平的激活。

生物活性

ITSA-1 is an activator of histone deacetylase (HDAC), and counteract trichostatin A (TSA)-induced cell cycle arrest, histone acetylation, and transcriptional activation.

体外研究

ITSA1 (50 μM; A549 cells) treatment serves to revert the TSA-arrested population to a normal cell cycle distribution. ITSA1 is also able to effect cell cycle rescue over longer duration.
ITSA1 (50 μM; 5 hours; A549 cells) treatment reduces the number of apoptosis in TSA-treated cells.
ITSA1 (50 μM; 2 hours; A549 and murine ES cells cells) treatment suppresses TSA-induced histone acetylation. Importantly, suppression of acetylation levels is only observable when ITSA1 is added concurrent with or post TSA treatment.
ITSA1 (50 μM; 30 minutes; murine ES cells cells) suppresses TSA-activated transcription in murine ES cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis

Cell Line:	Murine ES cells
Concentration:	50 μM
Incubation Time:
Result:	Served to revert the TSA-arrested population to a normal cell cycle distribution.

Apoptosis Analysis

Cell Line:	A549 cells
Concentration:	50 μM
Incubation Time:	5 hours
Result:	Reduced the number of apoptosis.

Western Blot Analysis

Cell Line:	A549 and murine ES cells
Concentration:	50 μM
Incubation Time:	2 hours
Result:	Reduced histone acetylation to the baseline level.

RT-PCR

Cell Line:	Murine ES cells
Concentration:	50 μM
Incubation Time:	30 minutes
Result:	Suppressed TSA-activated transcription.

体内研究
(In Vivo)

ITSA-1 (0.5 mg/kg; intraperitoneal injection; 3 times/week; for 8 weeks; CBS^+/− mice) treatment balances deacetylation activity and suppresses IL-6 and TNF-α expression and thereby attenuated histone acetylationdependent infammatory signaling.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	CBS^+/− mice
Dosage:	0.5 mg/kg
Administration:	Intraperitoneal injection; 3 times/week; for 8 weeks
Result:	Balanced deacetylation activity and suppressed IL-6 and TNF-α expression.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	CBS^+/− mice
Dosage:	0.5 mg/kg
Administration:	Intraperitoneal injection; 3 times/week; for 8 weeks
Result:	Balanced deacetylation activity and suppressed IL-6 and TNF-α expression.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	CBS^+/− mice
Dosage:	0.5 mg/kg
Administration:	Intraperitoneal injection; 3 times/week; for 8 weeks
Result:	Balanced deacetylation activity and suppressed IL-6 and TNF-α expression.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 32 mg/mL (109.54 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.4233 mL	17.1163 mL	34.2325 mL
5 mM	0.6847 mL	3.4233 mL	6.8465 mL
10 mM	0.3423 mL	1.7116 mL	3.4233 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (8.56 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (8.56 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (8.56 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (8.56 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (8.56 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (8.56 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。